Cannabis as a risk factor for psychosis in vulnerable teens: Implications for treatment

Primary Psychiatry

Volumn 15, Issue 6, 2008, Pages 51-57

  Bodkin, Lauren L ^a   Singh, Anjuli ^b   Corcoran, Cheryl ^a,c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals

^c Department of Clinical Psychiatry ^*

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ADOLESCENCE; BEHAVIOR; CANNABIS ADDICTION; COHORT ANALYSIS; COMPARATIVE STUDY; COMPREHENSION; EDUCATION; FAMILY HISTORY; GENETIC DIFFERENCE; GENETIC VARIABILITY; HUMAN; HYPOTHESIS; INTERVENTION STUDY; JUVENILE; MOTIVATION; PHYSICIAN; POPULATION; PROSPECTIVE STUDY; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SAMPLING; SCHIZOTYPAL PERSONALITY DISORDER; SYMPTOM;

EID: 45349104422     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. NIDA. Marijuana. Available at: www.nida.nih.gov/DrugPages/Marijuana.html/ . Accessed April 17, 2008.
2. Pope HG Jr, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA. 1996;275(7):521-527.
3. Harder S, Reitbrock S. Concentration-effect relationship of delta-9-tetrahydrocannabinol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther. 1997;35(4):155-159.
4. Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med. 1988;318(6):347-351.
5. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-28.
6. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci. 2007;8(11):885-895.
7. Weiser M, Davidson M, Noy S. Comments on risk for schizophrenia. Schizophr Res. 2005;79(1):15-21.
8. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004;184:110-117.
9. Mortensen PB, Pedersen CB, Westergaard T, et al. Effects of family history and place and season of birth on the risk of schizophrenia. N Engl J Med. 1999;340(8):603-608.
10. Mueser KT, Nishith P, Tracy JI, DeGirolamo J, Molinaro M. Expectations and motives for substance use in schizophrenia. Schizophr Bull. 1995;21(3):367-378.
11. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry. 1996;53(11):1022-1031.
12. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264(19):2511-2518.
13. Cantwell R, Brewin J, Glazebrook C, et al. Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry. 1999;174:150-153.
14. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci. 2003;28(1):48-54.
15. Pencer A, Addington J, Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Res. 2005;133(1):35-43.
16. Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry. 2000;34(3):468-475.
17. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117-1127.
18. Carlsson A. The dopamine theory revisited. In: Hirsch SR, Weiberger DR, eds. Schizophrenia. Oxford, UK: Blackwell Science; 1995:379-400.
19. Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med. 2003;33(1):23-32.
20. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558-1572.
21. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594-608.
22. Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-o-methyltransferase Val(158)Met moderation of delta-9- tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31(12):2748-2757.
23. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2002;164(4):407-415.
24. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. 2001;107(3):173-177.
25. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31(3):608-612.
26. Kwapil TR. A longitudinal study of drug and alcohol use by psychosis-prone and impulsive-nonconforming individuals. J Abnorm Psychol. 1996;105(1):114-123.
27. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend. 1996;42(3):201-207.
28. Caton CL, Hasin DS, Shrout PE, et al. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Br J Psychiatry. 2007;190:105-111.
29. Miller P, Lawrie SM, Hodges A, Clafferty R, Cosway R, Johnstone EC. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2001;36(7):338-342.
30. Miller PM, Johnstone EC, Lawrie SM, Owens DG. Substance use, psychiatric symptoms and the onset of schizophrenic illness. J Subst Abuse. 2006;11(2):101-113.
31. Dumas P, Saoud M, Bouafia S, et al. Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Res. 2002;109(1):27-35.
32. Nunn JA, Rizza F, Peters ER. The incidence of schizotypy among cannabis and alcohol users. J Nerv Ment Dis. 2001;189(11):741-748.
33. Skosnik PD, Spatz-Glenn L, Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res. 2001;48(1):83-92.
34. Williams JH, Wellman NA, Rawlins JN. Cannabis use correlates with schizotypy in healthy people. Addiction. 1996;91(6):869-877.
35. Spencer C. Motives that maintain cannabis use among individuals with psychotic disorders. In: Castle D, Murray R, eds. Marijuana and Madness. Cambridge MA: Cambridge University Press; 2004:166-185.
36. Lee CM, Neighbors C, Woods B. Marijuana motives: young adults' reasons for using marijuana. Addict Behav. 2007;32:1384-1394.
37. Brodbeck J, Matter M, Page J, Moggi F. Motives for cannabis use as a moderator variable of distress among young adults. Addict Behav. 2007;32(8):1537-1545.
38. Rey JM, Martin A, Krabman P. Is the party over? Cannabis and juvenile psychiatric disorder: the past 10 years. J Am Acad Child Adolesc Psychiatry. 2004;43(10):1194-1205.
39. Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W. Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry. 2007;46(3):408-417.
40. Macleod J, Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363(9421):1579- 1588.
41. Green B, Ritter C. Marijuana use and depression. J Health Soc Behav. 2004;41(1):40-49.
42. Windle M, Wiesner M. Trajectories of marijuana use from adolescence to young adulthood: predictors and outcomes. Dev Psychopathol. 2004;16(4):1007-1027.
43. Fergusson DM, Horwood LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction. 1997;92(3):279-296.
44. Gruber AJ, Pope HG, Hudson JI, Yurgelun-Todd D. Attributes of long-term heavy cannabis users: a case-control study. Psychol Med. 2003;33(8):1415-1422.
45. Jacobsen LK, Mencl WE, Westerveld M, Pugh KR. Impact of cannabis use on brain function in adolescents. Ann N Y Acad Sci. 2004;1021:384-390.
46. Tims FM, Dennis ML, Hamilton N, et al. Characteristics and problems of 600 adolescent cannabis abusers in outpatient treatment. Addiction. 2002;97(suppl 1):46-57.
47. Maharajh HD, Konings M. Cannabis and suicidal behaviour among adolescents: a pilot study from Trinidad. Scientific World Journal. 2005;5:576-585.
48. Shedler J, Block J. Adolescent drug use and psychological health. A longitudinal inquiry. Am Psychol. 1990;45(5):612-630.
49. Baigent M, Holme G, Hafner RJ. Self reports of the interaction between substance abuse and schizophrenia. Aust N Z J Psychiatry. 1995;29(1):69-74.
50. Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004;66(2-3):125-135.
51. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry. 1991;148(2):224-230.
52. Glynn SM, Sussman S. Why patients smoke. Hosp Community Psychiatry. 1990;41(9):1027-1028.
53. Mueser KT, Nishith P, Tracy JI, DeGirolamo J, Molinaro M. Expectations and motives for substance use in schizophrenia. Schizophr Bull. 1995;21(3):367-378.
54. Schofield D, Tennant C, Nash L, et al. Reasons for cannabis use in psychosis. Aust N Z J Psychiatry. 2006;40(6-7):570-574.
55. Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. Am J Addict. 2007;16(5):331-342.
56. Haney M, Ward AS, Comer SD. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl). 2001;155(2):171-179.
57. McDowell D, Levin FR, Brooks DJ, et al. Treatment of canna bis-dependent treatment seekers: a double-blind comparison of nefazodone, bupropion and placebo. Paper presented at: the 68th Annual Scientific Meeting of the College on Problems of Drug Dependence. June 17-22, 2006; Scottsdale, AZ.
58. Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decrease anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl). 2003;165(2):157-165.
59. Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: effects of oral THC or divalproez. Neuropsychopharmacology. 2004;29(1):158-170.
60. Levin FR, Mcdowell D, Evans SM, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict. 2004;13(1):21-32.
61. Huestis MA, Boyd SJ, Heishman SJ, et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl). 2007;194(4):505-515.
62. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2002;164(4):407-415.
63. Diamond G, Godley SH, Liddle HA, et al. Five outpatient treatment models for adolescent marijuana use: a description of Cannabis Youth Treatment interventions. Addiction. 2002;97(suppl 1):70-83.
64. Dennis M, Titus JC, Diamond G, et al. The Cannabis Youth Treatments (CYT) experiment: rationale, study design and analysis plans. Addiction. 2002;97(suppl 1):16-34.
65. French MT, Roebuck MC, Dennis ML, et al. The economic cost of outpatient marijuana treatment for adolescents: findings from multi-site field experiment. Addiction. 2002;97(suppl 1):84-97.
66. Dennis M, Godley SH, Diamond G, et al. The Cannabis Youth Treatment (CYT) study: main findings from two randomized trials. J Subst Abuse Treat. 2004;27(3):197-213.
67. Edwards J, Elkins K, Hinton M, et al. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand. 2006;114(2):109-117.
68. Addington J, Addington D. Impact of an early psychosis program on substance use. Psychiatr Rehabil J. 2001;25(1):60-67.
69. NIDA. Marijuana: Facts for Teens. Available at: www.nida.nih.gov/ MarijBroch/Marijteens.html. Accessed April 17, 2008.